FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# OMB APPROVAL 3235-0287

Estimated average burden hours per response: 0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Bonaccorso Joe						2. Issuer Name <b>and</b> Ticker or Trading Symbol  Verrica Pharmaceuticals Inc. [ VRCA ]									5. Relationship of Reporting Person(s) to Is (Check all applicable)  Director 10% Ov.  Officer (give title Other (s				
(Last)	(Fir	st) (MARMACEUTICA	NC.	3. Date of Earliest Transaction (Month/Day/Year) 07/22/2024							<b>V</b>	below	below) CHIEF COMME		below)	·			
44 WEST GAY STREET, SUITE 400						4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	<ol> <li>Individual or Joint/Group Filing (Check Application)</li> <li>Form filed by One Reporting Person</li> </ol>				
(Street) WEST CHESTE	•												V	Form filed by More than One Reporting Person					
					Rule 10b5-1(c) Transaction Indication														
(City)	(State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													nded to
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day						Execution Date,		ate,	Transaction Disposed Of Code (Instr. 5)			s Acquired (A) or f (D) (Instr. 3, 4 and			5. Amo Securit Benefic Owned Report	ties cially I Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) o (D)	Pr	rice	Transa	ransaction(s)			(111511.4)	
Common Stock 07/22/20					024				S		25,461(1)	D	\$	7.06(2)	10	6,931		D	
Common Stock 07/23/20					024				S		115(1)	D		\$6.98	106,816			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerci Expiration Dat (Month/Day/Ye		ate	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amou or Numb of Share	oer					

### **Explanation of Responses:**

- 1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.00 to \$7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

/s/ Mark Ballantyne, Attorney-07/23/2024

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.